Skip to content
Screener

Insmed INSM Q1 2025 earnings

Reported May 8, 2025 · Before market open

Revenue$92.8MBeat by $1.4M
EPS-$1.42Miss by $0.08
Revenue estimate$91.5M
EPS estimate-$1.34

Next report

Oct 29, 2026 (in 2 months)
Revenue estimate$501.2M
EPS estimate-$0.37

Financials

Q1 2025

Income statement

See full
Revenue$92.8M+22.9%
Gross profit$71.5M+23.3%
Operating income-$248.1M-70.5%
Net income-$256.6M-63.3%
EPS (diluted)-$1.42-34.0%

Balance sheet

See full
Cash & equivalents$403.2M-32.3%
Total debt$1.1B-5.6%
Total equity$99.2M+121%
Total assets$1.8B+55.5%

Cash flow

See full
Operating cash flow-$262.1M-42.4%
CapEx$10.1M+115%
Free cash flow-$272.2M-44.2%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$13.81B+251%
Enterprise value$14.55B+220%
P/S36.2×+23.8×

Profitability

See full
Gross margin76.5%-1.6pp
Operating margin-257.4%+45.0pp
Net margin-265.9%+37.4pp
FCF margin-207.1%+25.7pp

Returns & leverage

See full
Debt / equity11.5×—
Current ratio5.9×+4.1×

Segments

By product

See full
ARIKAYCE external R&D expenses$92.8M—

FAQ

When did Insmed report Q1 2025 earnings?
Insmed (INSM) reported Q1 2025 earnings on May 8, 2025 before market open.
What were Insmed's Q1 2025 revenue and EPS?
Insmed reported revenue of $92.8M and eps of $-1.42 for Q1 2025.
Did Insmed beat estimates in Q1 2025?
Revenue beat the consensus estimate of $91.5M by $1.4M. EPS missed the consensus estimate of $-1.34 by $0.08.
How did Insmed's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 22.9% from $75.5M a year earlier and eps declined 34.0% from $-1.06.
Where can I find Insmed's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001140361-25-017858) and the 10-Q periodic report (0001104506-25-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.